Programme: BIochemistry
Permanent URI for this collectionhttp://itsupport.cu.edu.ng:4000/handle/123456789/28779
Here you will find works strictly related to Biochemistry
Browse
5 results
Search Results
Item Advancements in Biomarkers of Prostate Cancer: A Review(Technology in Cancer Research & Treatment Volume 23, 2024) Agbetuyi-Tayo, Praise; Gbadebo, Mary; Rotimi, Oluwakemi A.; Rotimi, SolomonO.Prostate cancer (PCa) is one of the most prevalent and deadly cancers among men, particularly affecting men of African descent and contributing significantly to cancer-related morbidity and mortality worldwide. The disease varies widely, from slow-developing forms to highly aggressive or potentially fatal variants. Accurate risk stratification is crucial for making therapeutic decisions and designing adequate clinical trials. This review assesses a broad spectrum of diagnostic and prognostic biomarkers, many of which are incorporated into clinical guidelines, including the Prostate Health Index (PHI), 4Kscore, STHLM3, PCA3, SelectMDx, ExoDx Prostate Intelliscore (EPI), and MiPS. It also highlights emerging biomarkers with preclinical support, such as urinary non-coding RNAs and DNA methylation patterns. Additionally, the review explores the role of tumor-associated microbiota in PCa, offering new insights into its potential contributions to disease understanding. By examining the latest advancements in PCa biomarkers, this review enhances understanding their roles in disease managementItem Leveraging Epigenetic Biomarkers and CRISPR-Cas12a for Early Prostate Cancer Detection in Sub-Saharan Africa: Opportunities and Challenges(Preprints, 2026) Nguedia,Niels K.; Amadi, Emmanuel C.; Kintung, lrrinus F.; Ogunlana, Olubanke 0.; Chinedu, Shalom NItem Leveraging Epigenetic Biomarkers and CRISPR-Cas12a for Early Prostate Cancer Detection in Sub-Saharan Africa: Opportunities and Challenges(2025) Nguedia, Niela K.; Amadi, Emmanuel C.; Kintung, Irrinus F.; Ogunlana, Olubanke O.; Chinedu, Shalom N.Item Vitamin D Receptor Polymorphism and its Clinical Relevance in Prostate and Colon Cancer Patients: A Study in a Tertiary Institution in Nigeria(Journal of Radiation and Cancer Research, 2025-10) Aje, Eben A.; Sowunmi, Anthonia; Alabi, Adewumi; Agbakwuru, Chidi; Oshikanlu, Bukola; Rotimi, Solomon O.; Bashir, Maryam; Rotimi, Oluwakemi; Habeebu, Muhammad; Bolanle, AdegboyegaIntroduction: This study examines the clinical relevance of Vitamin D receptor (VDR) polymorphisms in prostate and colon cancer patients at NSIA LUTH Cancer Centre, Lagos, Nigeria. With limited African data on Vitamin D’s genetic role in cancer, we investigate its association with cancer susceptibility, grade, and stage. Methods: A total of 142 cases and controls were recruited, including newly diagnosed and treated prostate and colon cancer patients. The study received ethical approval from the Lagos University Teaching Hospital Ethical Committee and was self‑funded. Serum Vitamin D levels were assessed using ELISA, while VDR polymorphisms (Fok1, BsmI, TaqI, and ApaI) were analyzed via restriction fragment length polymorphism‑polymerase chain reaction. Results: The study found a significant association between Vitamin D deficiency and both prostate and colon cancers. Serum Vitamin D levels declined with increasing cancer grade and stage. In colon cancer, Vitamin D levels dropped from 43.8 ng/ml in stage I to 34.9 ng/ml in stage IV. In prostate cancer, a sharp decline was observed from 62.6 ng/ml in stage I to 29.8 ng/ml in stage IV. Patients with low Vitamin D levels had higher cancer risk (odds ratio [OR]: 3.1 for colon cancer; OR: 2.2 for prostate cancer). VDR polymorphism analysis revealed significant associations between cancer cases and specific genotypes: Fok1 (FF), BsmI (Bb), TaqI (tt), and ApaI (aa). Patients with these polymorphisms had lower Vitamin D levels, suggesting a genetic predisposition to cancer progression. Conclusion: This study highlights the impact of Vitamin D deficiency and VDR polymorphisms on prostate and colon cancer biology. The findings emphasize their potential roles in disease progression and suggest further research into Vitamin D supplementation as a protective measure in cancer patientsItem Advancements in Biomarkers of Prostate Cancer: A Review(2024) Agbetuyi-Tayo, Praise; Gbadebo, Mary; Rotimi, OluwakemiA.; Rotim, Solomon OProstate cancer (PCa) is one of the most prevalent and deadly cancers among men, particularly affecting men of African descent and contributing significantly to cancer-related morbidity and mortality worldwide. The disease varies widely, from slow-devel oping forms to highly aggressive or potentially fatal variants. Accurate risk stratification is crucial for making therapeutic decisions and designing adequate clinical trials. This review assesses a broad spectrum of diagnostic and prognostic biomarkers, many of which are incorporated into clinical guidelines, including the Prostate Health Index (PHI), 4Kscore, STHLM3, PCA3, SelectMDx, ExoDx Prostate Intelliscore (EPI), and MiPS. It also highlights emerging biomarkers with preclinical support, such as urinary non-coding RNAs and DNA methylation patterns. Additionally, the review explores the role of tumor-associated microbiota in PCa, offering new insights into its potential contributions to disease understanding. By examining the latest advance ments in PCa biomarkers, this review enhances understanding their roles in disease management.